# PainReform Ltd. (PRFX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $1.55 (+9.15%)

> PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management. Its core product, PRF-110, is designed as an oil-based, viscous solution applied directly into the surgical wound bed before closure to provide localized and extended analgesia. The company’s work centers on improving drug delivery in areas where sustained pain control and targeted treatment are important, particularly in hospital-based surgical settings. PainReform Ltd. operates in the healthcare and drug development sectors, where it contributes to the development of specialized treatment options built around existing active ingredients and delivery technologies. Headquartered in Israel, the company remains focused on advancing products intended for post-operative care and other clinical applications.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/PRFX)